COSTA MESA, California – 1 February 2011 – IOP Ophthalmics, the premier developer and distributor of specialty surgical technologies for eye surgery, announced today the promotion of Jay Tardugno to Regional Sales Director. This new appointment commenced on January 1st, 2011.
Jay initially joined IOP Ophthalmics in 2005 as an independent surgical sales representative – promoting and servicing surgical technologies to hospitals, ASCs and surgeon practices.
Jay Tardugno Promoted
JT’s dynamic personality and zealous commitment to his customers established him as a leader in the field and the O.R.
His rich experience in the industry has served and prepared him well. From 1993 to 2005, Jay served as surgical and territorial manager for Allergan Pharmaceuticals, Bausch & Lomb Surgical, Coherent Medical Laser Group and Inspire Pharmaceuticals. His performances routinely ranked him in the upper echelons of sales hierarchy.
His new position will allow IOP Ophthalmics to benefit from Jay’s passion, leadership, dedication and competitiveness. He will be responsible for managing and supervising the company’s Midwest surgical sales force.
Comments from Erich Ziegler, Vice President: “Our company is preparing to grow. We need great people. Our priority #1 is to court and retain the finest individuals in the industry. Promoting Jay was an easy decision – in light of his experience and obvious commitment to IOP. We are blessed to have Jay in a higher profile role and capacity.”
JT – a native New Englander – lives in Methuen, Massachusetts. He’s a graduate of Boston University, where he lettered and on the varsity football team for 4 years.
About IOP Ophthalmics Founded in 1988, IOP, Inc. develops and commercializes specialized, leading-edge surgical technologies for eye surgery. IOP's purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider. IOP currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for cornea, anterior and oculoplastic surgeries.